Mutations in CDC45, Encoding an Essential Component of the Pre-Initiation Complex, Cause Meier-Gorlin Syndrome and Craniosynostosis

Aimee L. Fenwick,1,18 Maciej Kliszczak,1,2,18 Fay Cooper,3,18 Jennie Murray,3 Luis Sanchez-Pulido,3 Stephen R.F. Twigg,1 Anne Goriely,1 Simon J. McGowan,4 Kerry A. Miller,1 Indira B. Taylor,1 Clare Logan,3 WGS500 Consortium, Sevcan Bozdogan,5 Sumita Danda,6 Joanne Dixon,7 Solaf M Elsayed,8 Ezzat Elsobky,8 Alice Gardham,9 Mariette J V Hoffer,10 Marije Koopmans,10 Donna M. McDonald-McGinn,11 Gijs W E Santen,10 Ravi Savarirayan,12 Deepthi de Silva,13 Olivier Vanakker,14 Steven A. Wall,15 Louise C. Wilson,9 Ozge Ozalp Yuregir,16 Elaine H. Zackai,11 Chris P. Ponting,3 Andrew P Jackson,3,19 Andrew O. M. Wilkie,1,15,19 Wojciech Niedzwiedz,2,* Louise S Bicknell3,17,*

1Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; 2Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; 3MRC Human Genetics Unit, IGMM, University of Edinburgh, Edinburgh EH4 2XU, UK; 4Computational Biology Research Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; 5Department of Medical Genetics, Mersin University, Mersin, 33343 Cukurova, Turkey; 6Department of Clinical Genetics, Christian Medical College and Hospital, Vellore, Tamil Nadu 632004, India; 7Genetic Health Service NZ-South Island Hub, Christchurch Hospital, Christchurch, Canterbury 8140, New Zealand; 8Children’s Hospital, Ain Shams University, Cairo 11566, Egypt; 9North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street Hospital, London WC1N 3JH, UK; 10Department of Clinical Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; 11Clinical Genetics, The Children's Hospital of Philadelphia, 34th & Civic
Center Boulevard, Philadelphia, PA 19104, USA; 12Victorian Clinical Genetics Services, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Victoria 3052, Australia; 13Department of Physiology, Faculty of Medicine, University of Kelaniya, Gampaha GQ 11010, Sri Lanka; 14Center for Medical Genetics, Ghent University Hospital, B-9000 Ghent, Belgium; 15Craniofacial Unit, Department of Plastic and Reconstructive Surgery, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK; 16Genetic Diagnosis Center, Adana Numune Training and Research Hospital, Cukurova, Adana, 01170, Turkey; 17Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, Otago 9016, New Zealand.

These authors contributed equally to this work.

These authors contributed equally to this work and are co-senior authors.

*Correspondence: wojciech.niedzwiedz@imm.ox.ac.uk (W.N.), louise.bicknell@otago.ac.nz (L.S.B.)

Abstract
DNA replication precisely duplicates the genome to ensure stable inheritance of genetic information. Impaired licensing of origins of replication during the G1 phase of the cell cycle has been implicated in Meier-Gorlin syndrome (MGS), a disorder defined by the triad of short stature, microtia and a/hypoplastic patellae. Biallelic partial loss-of-function mutations in multiple components of the pre-replication complex (preRC; ORC1, ORC4, ORC6, CDT1 or CDC6) as well as de novo activating mutations in the licensing inhibitor, GMNN, cause MGS. Here we report the identification of mutations in CDC45 in 15 affected individuals from 12 families with MGS and/or craniosynostosis. CDC45 encodes a component of both the pre-initiation (preIC) and CMG helicase complexes, required respectively for initiation of DNA replication origin firing and ongoing DNA synthesis during S-phase itself, hence is functionally distinct from previously identified MGS genes. The phenotypes of affected individuals range from syndromic coronal craniosynostosis to severe growth restriction, fulfilling diagnostic criteria for Meier-Gorlin syndrome. All mutations identified were biallelic and included synonymous mutations altering splicing of physiological CDC45 transcripts, as well as amino acid substitutions expected to result in partial loss of function. Functionally, mutations reduce levels of full-length transcripts and protein in subject cells, consistent with partial loss of CDC45 function and a predicted limited rate of DNA replication and cell proliferation. Our findings therefore implicate the preIC as an additional protein complex involved in the etiology of MGS, and connect the core cellular machinery of genome replication with growth, chondrogenesis and cranial suture homeostasis.
Introduction

Replication of DNA during eukaryotic cell division is an essential process, which requires a complex apparatus of conserved proteins operating under tight temporal and regulatory control. Although the duplication process itself occurs during the S (synthesis) phase of the cell cycle, the initial components assemble on DNA much earlier, during the late mitotic stages and in G1 phase.

In the first stage, the pre-replication complex (preRC) is formed by the 6-subunit origin recognition complex (ORC) binding to replication origins distributed throughout the genome (Figure 1).\(^1\) ORC recruits CDT1 and CDC6, which leads to the binding of the inactive MCM2-7 helicase as a double hexamer at replication origins.\(^2\) At the G1/S transition the pre-initiation complex (preIC) proteins assemble in a two-step DDK- and CDK-dependent manner\(^3\) and through interaction with the MCM helicase enable binding by the CDC45 and GINS1-4 proteins. This creates the activated CMG helicase, an eleven-subunit complex that possesses essential DNA unwinding activity, allowing polymerases access to DNA and enabling replication to commence.\(^4\)-\(^8\) CDC45 has single-stranded DNA binding activity, facilitating DNA strand displacement at the replication fork.\(^9\) Hence CDC45 plays a central role both in initiation of DNA replication origin firing (preIC) and ongoing DNA synthesis (CMG helicase), and genetic studies demonstrate that it is essential in both yeast and mice.\(^10\)-\(^14\) Both *in vitro* and *in vivo* data indicate that CDC45 is loaded onto chromatin specifically in the S phase of the cell cycle, after the assembly of the preRC complexes.\(^11\); \(^14\)-\(^17\)

Several Mendelian syndromes have been associated with mutations in components of the DNA replication machinery. Meier-Gorlin syndrome (MGS) (MIM 224690) is characterised by short stature, microtia (small ears) and aplasia or hypoplasia of the patellae.\(^18\) Biallelic mutations in multiple components of the preRC (*ORC1* [MIM 601902], *ORC4* [MIM 603056], *ORC6* [MIM 607213], *CDT1* [MIM 605525] and *CDC6* [MIM
were identified in individuals with MGS, and among them, mutations in these genes account for approximately 70% of cases. Recently, de novo mutations in three individuals were reported in the CDT1 inhibitor, GMNN (MIM 602842), resulting in the omission of a degron domain that stabilises GMNN levels and is consequently predicted to impair licensing in subject cells.

Here, we provide genetic and functional evidence that mutations in CDC45 (MIM 603465) cause human disease. We describe 15 individuals with biallelic partial loss of function mutations in CDC45 and demonstrate a phenotype that extends from syndromic craniosynostosis to classical MGS.

**Subjects and Methods**

**Clinical studies**

The clinical studies were approved by Oxfordshire Research Ethics Committee B (reference C02.143), London Riverside Research Ethics Committee (reference 09/H0706/20), Scottish Multicentre Research Ethics Committee (04:MRE00/19) and the Medisch Ethische Toetsingscommissie of the Leiden University Medical Center (LUMC) (P14-029). Subjects were enrolled into the craniosynostosis cohort based on referral from a craniofacial unit or clinical genetics department, with craniosynostosis proven on either plain radiographs or computed tomography (CT) of the skull. Individuals in the MGS cohort were clinically diagnosed by the referring clinician; in those from whom clinical data were available, all demonstrated hypoplastic or absent kneecaps, small or simple ears, and facies typical of MGS (small mouth and full lips). All participants gave informed consent, and separate permission was obtained for publication of clinical photographs.
Whole genome and exome sequencing

Subjects P1 and P2, from a craniosynostosis cohort, were subjected to whole genome sequencing and exome sequencing, respectively. Exome sequencing of subject P4 was undertaken by Oxford Gene Technology, as part of a study of subjects with primordial dwarfism (characterised by in utero growth retardation, and head circumference and height more than 4 standard deviations below the age- and gender-matched population mean). Exome sequencing of family P12 was undertaken as part of a diagnostic approach to mutation identification. All details of sequencing library preparations and platforms, as well as software tools for mapping, alignment and variant calling and prioritization are presented in Table S1.

Genomic analysis of CDC45

To investigate further the significance of the CDC45 variants, primers were designed for amplification of genomic DNA (GenBank: NT_011520.13) and cDNA (GenBank: NM_003504.4; see Supplemental Data, Note on accession numbers for CDC45). We used dideoxy-sequencing to confirm the identity of CDC45 variants identified during whole genome and exome sequencing, and analyzed their segregation in parents and unaffected siblings. Primer sequences and experimental conditions used for PCR amplification and sequencing are provided in Table S2. To analyze a larger number of individuals for CDC45 mutations, we used Fluidigm/Ion Torrent resequencing or dideoxy-sequencing, respectively, to screen CDC45 in DNA panels from subjects with craniosynostosis (467 samples) or MGS (34 samples), in whom mutations in known causative genes had not previously been identified (Table S2). Multiplex ligation-dependent probe amplification (MLPA) was used to confirm the intragenic deletion in family P12 (Table S2).
Analysis of CDC45 splicing

Total RNA was extracted from lymphoblastoid cell lines using Trizol reagent (Invitrogen) and the RNeasy kit (Qiagen) according to the manufacturer's instructions. DNA was removed by treatment with DNase I (Qiagen). cDNA was generated using random oligomer primers and superscript II (Thermo Fisher) or the RevertAid First Strand Synthesis kit (Fermentas). Primers used for RT-PCR and qRT-PCR are listed in Table S3. cDNA levels were quantified by qRT-PCR using Brilliant II SYBR green qPCR master mix with passive ROX reference dye (Agilent Technologies) on the ABI Prism HT7900 Sequence Detection System. The relative expression of target genes to a control was calculated using the comparative CT method ($2^{\Delta\Delta CT}$) method.

Cell lines, chemicals, plasmids and transfections

Lymphoblastoid cell lines were cultured in RPMI-1640 supplemented with 15% fetal bovine serum (FBS) and 1% penicillin and streptomycin. Amniocytes were cultured in Amnio-MAX C-100 Complete Medium (Gibco). All reagents were purchased from Life Technologies unless otherwise stated.

Antibodies and Western blotting

Whole cell lysate was prepared using urea buffer (9 M urea, 50 mM Tris HCl, pH 7.3, 150 mM β-mercaptoethanol). Primary antibodies used were mouse anti-human CDC45 (sc55569, Santa Cruz Biotech) at 1:1000 and mouse anti-human TUBULIN (B512, Sigma) at 1:10000.

Protein alignments and structure prediction
Clustal Omega was used to generate multi-sequence alignments of orthologous CDC45 proteins. Accession numbers are: Homo sapiens NP_003495.1, Pan troglodytes XP_009436063.1, Canis lupus XP_543547.3, Mus musculus NP_033992.2, Gallus gallus XP_415070.2, Danio rerio NP_998551.1, Drosophila melanogaster NP_569880.1, Anopheles gambiae XP_320573.1, Caenorhabditis elegans NP_497756.2, Saccharomyces cerevisiae NP_013204.1, Schizosaccharomyces pombe NP_594693.1. The structural model of human CDC45 was modelled on the 3.7Å cryo-electron microscopy structure of S. cerevisiae Cdc45. It was created using Modeller and is presented using Pymol (Schrodinger).

Results

Exome and Genome Sequencing and Targeted Resequencing Identify Biallelic Variants in CDC45

Clinical whole genome sequencing of a trio comprising a male individual (P1) with syndromic unilateral coronal craniosynostosis and his unaffected parents, initially identified several candidate variants for further scrutiny. These were a single de novo missense mutation (FLRT1 [MIM: 604806] c.137C>T, p.T46M), two very rare (absent in dbSNP135, ESP or 1000 Genomes) hemizygous nonsynonymous variants (OPHN1 [MIM 300127] c.1559C>T, p.Thr520Ile and GEMIN8 [MIM 300962] c.500G>A, p.Arg167His) and two very rare compound heterozygous genotypes (CDC45 c.[318C>T; c.677A>G], p.[Val106=; Asp226Gly] and MYO10 [MIM 601481] c.[1491G>A; 5459A>C], p.[Glu497=; His1820Pro]). FLRT1 was initially prioritized for further analysis, but resequencing this gene in a panel of 230 individuals with craniosynostosis revealed no further mutations. During concurrent exome sequencing of female subject P2 with syndromic bilateral coronal craniosynostosis, variant analysis under a recessive model of inheritance also identified two
very rare predicted missense changes in \textit{CDC45} (c.226A>C, p.Asn76His and c.469C>T, p.Arg157Cys); dideoxy-sequencing of parental samples showed that the CDC45 variants were present in a compound heterozygous (biallelic) state. Given the identification of two individuals with unilateral or bilateral coronal or craniosynostosis, each of whom had two rare biallelic variants in \textit{CDC45} (Table 1), resequencing of \textit{CDC45} was undertaken in a further 467 subjects with craniosynostosis. This revealed one further individual (P3) with two rare \textit{CDC45} variants (Table 1), which analysis of parental samples showed were also biallelic. Consistent with a causal role in the disease state, three unaffected siblings of P1 and P2 inherited different combinations of \textit{CDC45} alleles (Figure 2A).

In addition to craniosynostosis, clinical features variably present in individuals P1-P3 included mild short stature, microcephaly and ear anomalies (Figure 2B, Table 2). In view of the previous association of replication-associated genes with growth restriction,\textsuperscript{19-22} we interrogated exome sequencing data from a cohort of individuals with primordial dwarfism (n = 52) for variants in \textit{CDC45}. One individual (P4), diagnosed with MGS, was found to harbor two rare \textit{CDC45} variants (Table 1).

Given the presentation of subject P4 with MGS, we then undertook dideoxy-sequencing of 34 further subjects with MGS, in whom causative mutations had not previously been found in preRC components. This identified seven further families (P5-P11) (Table 1), in which nine individuals have biallelic mutations in \textit{CDC45}. All variants had either a very low allele frequency in control populations with no homozygotes, appropriate for a rare recessively inherited Mendelian disorder, or were absent from the ExAC dataset. The autosomal recessive inheritance was confirmed by appropriate segregation in all parents where available (Figure 2A, Table 1).

Concurrently, exome sequencing was undertaken in a nonconsanguineous Dutch family in which two consecutive fetuses displayed craniosynostosis and additional anomalies in
The recurrence within the family suggested an autosomal recessive inheritance, however no candidate disease genes were identified following bioinformatic analysis and filtering of the exome data. Given the previous findings, CDC45 and other autosomal recessive craniosynostosis disorder associated genes were manually re-examined; this identified a single paternally transmitted missense variant in CDC45, c.893C>T encoding p.Ala298Val. Visual analysis of the sequencing reads using Integrated Genomics Viewer suggested lower coverage of exon 5 in both the two affected samples and the maternal sample compared with the paternal sequencing (Figure S1A). Analysis using MLPA probes confirmed a deletion encompassing only exon 5 of CDC45 in these three samples (Figure S1B). This would be predicted to delete a highly conserved portion of the protein, but translation would remain in-frame and therefore transcripts from this allele would not be predicted to undergo nonsense-mediated decay. This was confirmed by analysis of cDNA derived from maternal blood (Figure S1C).

The human CDC45 mutational spectrum indicates partial loss of protein function

CDC45 is an essential component in the preIC that establishes active replication at licensed origins (Figure 1). The majority of variants identified in CDC45 lead to amino acid substitutions (Figure 3A), which bioinformatic analysis predict to be damaging; we examined conservation of these residues as a measure of deleteriousness, and found all are conserved in vertebrates, with residues at several sites conserved through to yeasts (Figure 3B).

One conserved substitution, c.203A>G, p.Gln68Arg, occurred at the penultimate nucleotide in exon 3 suggesting that it might also impact on splicing in addition to any protein-level consequence (see next section). The three subjects (P4, P5, P8) with a truncating/null mutation (nonsense, frameshift deletion, or initiation codon mutation) on one allele all segregate an identical missense variant, c.1388C>T, p.Pro463Leu present on the
trans allele; given the South Asian ancestry in all three subjects (ExAC South Asian allele frequency 0.000062), the presence of this variant is compatible with a founder effect.

All individuals had at least one allele compatible with some residual function; none were biallelic for null mutations, consistent with the early embryonic lethality reported in a Cdc45 knockout mouse (Cdc45 homozygotes die before E7.5, due to impaired proliferation of the inner cell mass\textsuperscript{13}). Individuals who were compound heterozygotes for a loss-of-function and a substitution allele (p.Pro463Leu or p.Ala298Val) were particularly severely affected.

**Structural consequences of CDC45 mutations**

Missense mutations did not cluster within a specific domain of the protein (Figure 3A). However, a homology model derived from the recent high resolution cryo-electron microscopy study of the yeast CMG helicase complex\textsuperscript{30} demonstrated that a number of substituted residues are located within the core of the CDC45 protein (Figure 4A, B). This core region corresponds to the known catalytic site of the bacterial RecJ orthologs of CDC45 and its DHH phosphoesterase homologs\textsuperscript{31;32} Such substitutions would therefore be likely to perturb protein stability. In particular, the recurrent p.Pro463Leu substitution replaces a conserved proline residue with a likely essential role in N-capping of an alpha-helix (Figure 4C). Likewise, within the protein core the p.Asn76His substitution is expected to introduce a positive charge within, and thus disrupt, the predicted divalent cation coordination sphere present in many members of the DHH phosphoesterase superfamily (Figure 4D).\textsuperscript{33-35} Predictions of functional consequences for point mutations at other sites in the homology model were not possible, aside from the p.Pro321Thr substitution that is expected to disrupt the interaction of CDC45 with MCM2 (Figure 4E).
Hypomorphic *CDC45* Mutations act by Disrupting Transcript Splicing and Reducing Protein Levels

Five of the alleles (in families P1, P3, P9 and P10) were hypothesized to affect splicing (Table S4-, S5) and this was confirmed in the three samples available for extraction of RNA, in which we analyzed the effects of putative splicing mutations on cDNA.

In two families (P1, P9), the only putative second disease variants present after filtering to remove common variants were synonymous, which generally are less likely to be pathogenic. These two variants (c.318C>T and c.333C>T) lie close together in exon 4 which is skipped for transcripts in which alternative splicing from exon 3 directly to exon 5 generates a naturally occurring shorter isoform. This evolutionarily conserved instance of exon skipping is predicted to generate an in-frame protein product that lacks part of the highly conserved DHH phosphoesterase domain. RNA derived from these subjects (P1: c.318C>T, P9-1: c.333C>T) exhibited an increased ratio of exon 3/5 transcript to exon 3/4/5 cDNA product compared to controls (Figure 5). *In silico* tools (Human Splice Finder and Sroogle) predict the c.318C>T variant to disrupt exon splice enhancer sites, and the c.333C>T variant to enhance potential cryptic exonic splice silencer sites, both mechanisms by which these variants may promote the skipping of exon 4 (Table S5). The apparently nonsynonymous variant c.203A>G (mutation present in P9-1 and P9-2), which lies at the penultimate nucleotide of exon 3, was also shown to cause complete skipping of exon 3 in the cell line from P9-1 (Figure 5Bi).

We next sought to investigate the consequence of these mutations on the CDC45 protein by assessing protein levels in cells from five subjects by immunoblotting for endogenous CDC45. In the three cell lines available from affected individuals (lymphoblastoid cell lines derived from P1, P2 and P9-1) and in primary amniocytes derived from P12-1 and P12-2, CDC45 levels were significantly lower than in multiple control cells.
or cell lines ($P < 0.0001$). Moreover, CDC45 levels were reduced below 50% in all cases, indicating a contribution from both alleles to reduced protein levels. This suggests that the missense mutations present in these cells or cell lines (P1, p.Asp226Gly; P2, p.Asn76His and p.Arg157Cys; P12, p.Ala298Val) each result in destabilization of CDC45 protein.

Taken together with the nature of the mutations identified, the key demonstration of decreased cellular levels in several affected individuals confirm that variants identified were pathogenic and the mutations would most likely result in destabilization of CDC45 protein.

**Spectrum of Phenotypes associated with CDC45 Mutations and Correlation with Genotype**

In total we identified 15 subjects from 12 families with variants in *CDC45* (Table 1, Figure 2A). Individuals with biallelic *CDC45* mutations exhibit substantial variation in severity, in part explained by ascertainment from two distinct cohorts of affected subjects (craniosynostosis for P1-P3, P12 and MGS for P4-P11). Nevertheless they manifest a recognizable phenotypic spectrum with overlapping clinical features (Table 2, Figure 2B-D).

For example, although subjects P4-P11 all presented with the classical triad of MGS features (short stature from -1.3 to -7.7 SD, microtia and absent or hypoplastic patellae), craniosynostosis was also frequent, in contrast to MGS associated with mutations in preRC components. The severity of craniosynostosis varied widely from unilateral or bilateral coronal synostosis to multiple suture involvement (Figure 2C). The discordance for craniosynostosis in two siblings with identical mutations (P9-1 and P9-2), indicates that this is not a fully penetrant phenotype. Conversely, individuals with a primary presentation of craniosynostosis also exhibited mild MGS features, such as hypoplastic ears (P1, P3, P12-1), mild short stature, and a similar facial gestalt including a small mouth (Figure 2B). The MGS feature of patellar hypoplasia was however not observed in any of the three individuals with
craniosynostosis who presented postnatally (P1-P3). Thin eyebrows were present in subjects presenting with either craniosynostosis or MGS, a feature that has not been previously highlighted in these or related developmental disorders. Additionally, anal abnormalities (imperforate anus or anterior placement) were present in seven subjects drawn from both cohorts. Growth failure and microcephaly were evident from birth in almost all subjects (Figure 2D), and both the microcephaly and height reduction were progressive throughout childhood. Carrier parents and heterozygous siblings were phenotypically normal, a point of particular note since CDC45 is located on 22q11.21, within the interval deleted in the 22q11.2 deletion syndromes.39

Discussion

Here we identify multiple mutations in CDC45, implicating it is involved in the pathogenesis of both MGS and craniosynostosis. Previous work had established MGS as a disorder of replication licensing, with biallelic mutations in ORC 1, 4 and 6 and accessory proteins CDC6 and CDT1. Furthermore, a recent report has identified stabilizing mutations in GMNN, which likely act to inhibit CDT1 and consequently reduce licensing in G1.23 No mutations in any of the MCM subunits have been discovered in individuals with MGS, previously suggesting that MGS was limited to the upstream preRC components; indeed, a founder MCM4 mutation has been described causing a distinct entity - a genome instability syndrome of short stature, adrenal insufficiency and primary immunodeficiency.40-42 The identification of CDC45 is therefore surprising, given the well-established function of the CDC45 protein in replication activation and fork progression (Figure 1). Associating CDC45 mutations with MGS therefore expands understanding of the pathogenic basis of MGS, and given the number of individuals reported here, establishes CDC45 as a common cause of MGS syndrome, alongside ORC1 and CDT1. These mutations in individuals with MGS also raise the
possibility that mutations in genes coding for other proteins involved in DNA replication may be implicated in MGS and/or craniosynostosis.\textsuperscript{17, 43-45}

Following the initial identification of MGS mutations, several studies have proposed disease mechanisms distinct from the canonical role of the preRC in replication, such as dysregulated cilia formation or centrosome duplication.\textsuperscript{46, 47} Our identification of MGS mutations in distinct replication machinery, with similar growth and clinical characteristics seen in the preRC MGS individuals (including those with GMNN mutations), strongly favors a replication-based etiology for MGS. Notably, biallelic mutations in the helicase \textit{RECQL4} (MIM 603780, also required for preIC formation and replication initiation\textsuperscript{44, 45}), can cause a phenotype that overlaps with MGS; RAPADILINO syndrome (MIM 266280) is characterised by growth retardation and patellar agenesis, although diarrhoea, palatal anomalies and radial ray defects are also evident.\textsuperscript{45} Since CDC45 has been shown to bind several additional proteins in the preIC, for example TOPBP1\textsuperscript{48} and MCM10,\textsuperscript{49} mutations of these other components may in future be implicated in MGS or disorders exhibiting overlapping features.

A distinctive feature of MGS caused by \textit{CDC45} mutations is the frequent association with craniosynostosis. Only two previous MGS subjects have been reported with craniosynostosis, both with \textit{ORC1} mutations (P1 and P3 in Bicknell et al., 2011)\textsuperscript{19}, therefore it is likely that the presence of craniosynostosis in MGS subjects is a strong predictor for \textit{CDC45} mutations. Craniosynostosis is also a feature of Baller-Gerold syndrome (MIM 218600), another \textit{RECQL4} disorder,\textsuperscript{45} further implicating replication initiation in the etiology of premature cranial suture closure.

Disruption of the canonical function of CDC45 in replication initiation is consistent with the previously proposed models to explain the growth phenotype, which suggested that impaired replication in affected individuals disrupts cell division during periods of rapid proliferation in development, ultimately impairing organism growth and leading to a
‘hypocellular’ dwarfism.\textsuperscript{20, 50} Partial loss of function mutations in \textit{CDC45}, like those in preRC components, further indicate that strict regulation of replication is particularly required for the development of specific cartilaginous structures (ear, patella, trachea or bronchial tree),\textsuperscript{51} but the exact mechanism remains elusive and future studies with model organisms will be required. Similarly, the frequent occurrence of craniosynostosis in this cohort, along with the established premature suture fusion seen in subjects with \textit{RECQL4} mutations, highlights the importance of normal replication initiation and progression to maintain correct proliferation-differentiation balance in the cranial sutures.\textsuperscript{52}

In summary, we present genetic and functional evidence that mutations in \textit{CDC45} cause Meier-Gorlin syndrome with craniosynostosis. The identification of these mutations in a DNA replication protein functioning downstream to the previously identified MGS genes reinforces the premise that the growth and cartilaginous phenotypes of MGS, as well as the premature cranial suture fusion seen here, are due to replication dysfunction. This identification also suggests new candidate genes in which mutations might underlie this disorder or component phenotypes.

\textbf{Supplemental Data}

Supplemental Data contains Supplementary Notes, Tables S1-S5 and Figure S1.

\textbf{Acknowledgments}

We thank the families and clinicians for their participation; the IGMM core sequencing service; staff at the High-Throughput Genomics facility at the Wellcome Trust Centre for Human Genetics (Oxford) for Illumina sequencing, Tim Forshew and Francesco Marass for primer design, and Sue Butler, John Frankland and Tim Rostron for help with cell culture and
DNA sequencing. This work was supported by funding from the Medical Research Council (MRC) (A.P.J., L.S.P., C.P.P., W.N.) and through the WIMM Strategic Alliance (G0902418 and MC_UU_12025), the European Research Council (ERC, 281847) (A.P.J.), the Lister Institute for Preventative Medicine (A.P.J.), Medical Research Scotland (L.S.B.), Royal Society of New Zealand Rutherford Discovery Fellowship (L.S.B.), the Department of Health, UK, Quality, Improvement, Development and Initiative Scheme (QIDIS) (A.O.M.W.), Newlife Foundation for Disabled Children (SG/14-15/10 to A.O.M.W.), National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme (A.O.M.W.), and the Wellcome Trust (Project Grant 093329 to A.O.M.W. and S.R.F.T.; Investigator Award 102731 to A.O.M.W.). The authors declare no conflicts of interest.

Web Resources

The URLs for data presented herein are as follows:

1000 Genomes, http://browser.1000genomes.org
ExAC Browser, http://exac.broadinstitute.org/
Pymol, http://www.pymol.org
References


Figure Legends

Figure 1. Pre-Replication and Pre-Initiation Complexes in DNA Replication, Showing Components Mutated in MGS

Previously identified MGS genes (labelled with orange lettering) encode members of the pre-replication complex (preRC, upper cartoon); these components are involved in the licensing of replication origins during the G1 phase of the cell cycle. GMNN acts during other cell cycle phases to inhibit CDT1 but is degraded in late M (mitosis) phase (indicated by dotted GMNN), permitting free CDT1 to participate in origin licensing in G1. In contrast, CDC45 contributes at the next major step in DNA replication, in which the coordinated action of many replication initiation factors including RECQL4 forms the pre-initiation complex (PreIC, lower cartoon) to support the interaction of CDC45 and GINS1-4 with the MCM helicase, converting the latent form to an active helicase and initiating the unwinding of DNA.

Figure 2. Clinical Features of Individuals with Mutations in CDC45

(A) Pedigrees of families segregating mutations in CDC45. Note consanguinity in P5, P7 and P11 and that all parents and unaffected siblings available for testing were heterozygous for only one variant, consistent with autosomal recessive inheritance.

(B) Facial appearance of individuals with CDC45 mutations. Many individuals demonstrate the facial characteristics of MGS including microtia, small mouth, full lips and micrognathia, but there is a marked spectrum of severity across the cohort. Note the consistent appearance of thin eyebrows.

(C) CT head scans and plain skull radiographs of individuals with CDC45 mutations demonstrating premature fusion of cranial sutures. Note the discordance in suture fusion.
between sibs P9-1 and P9-2. Imaging of P8 indicates progressive suture closure (P8 left panel, age 2 yr 4 m, P8 right panel, age 3 yr 8 m). Skull radiography of P5 demonstrates a copper-beaten appearance of the skull.

(D) Individuals with \textit{CDC45} mutations have below average stature and many exhibited intrauterine growth retardation and microcephaly (both \textit{in utero} and postnatal). SD, standard deviation; Lgt, length; OFC, occipitofrontal circumference; Wgt, weight; Hgt, height. Blue, individuals derived from craniosynostosis cohort; black, individuals derived from MGS cohort.

**Figure 3. Mutations in CDC45, and Conservation of Substituted Residues in Orthologous Proteins**

(A) Mutations identified in \textit{CDC45} include variants predicted or shown to affect splicing (blue, position in gene shown in upper panel), predicted missense substitutions (black), or truncating mutations (purple). Δex5 refers to the intragenic deletion encompassing exon 5 of \textit{CDC45} in family P12 (green). Mutations do not cluster within any specific domain of CDC45. Domain architecture of human CDC45 indicated as described in Yuan \textit{et al.}\textsuperscript{26} The two alpha-beta domains are shown in purple and orange, respectively. The protruding helical motif (PHM) inserted in the first alpha-beta domain is shown in red. The middle all-helix interdomain (ID) is shown in blue, and the two linkers (L1 and L2) are shown in gray.

(B) Clustal Omega alignments of eukaryotic CDC45 proteins indicate mutated residues are well conserved, with several residues (such as p.Asn76His, p.Arg157Cys, p.Pro321Thr and p.Pro463Leu) conserved as distantly as fungi. Blue shading indicates proportion of conserved amino acids.
Figure 4. Structural Consequences of CDC45 Substitutions

(A) Structural model of human CDC45 demonstrating the spatial distribution of substitutions in the protein. Red boxes indicate position of missense mutations, with side-chains of these substituted residues displayed in green.

(B) CDC45 in context of the *S. cerevisiae* CMG complex from the 3.8Å cryo-electron microscopy structure.26

(C-E) Modeling of substitutions that cluster in the central core of CDC45. (C) Proline 463 is an evolutionarily conserved position, with an essential role in N-capping of the alpha-helix localized between Pro542 and Cys556 in yeast Cdc45 (Pro463 and Phe477 in human). Given the location of Pro463 in the CDC45 structural core, the substitution to leucine is predicted to have severe effects on the stability of this helix53 and therefore overall stability of the protein.

(D) Asn76 is predicted to be part of the divalent cation coordination sphere. While the DHH domain of CDC45 is currently considered to be catalytically inert,30; 54 residues D26, D28, D99 and H101, corresponding to the catalytic core of prokaryotic RecJ exonucleases and the DHH superfamily of phosphoesterases, are conserved (highlighted by black boxes).26; 32; 55 This suggests the continued presence of a divalent cation at this position (predicted divalent cation indicated by yellow sphere). Asn76 is therefore thought to be part of a divalent cation coordination sphere which, in other homologs, is the phosphoesterase catalytic centre. The substitution to histidine would introduce a positive charge into the putative divalent cation coordination sphere, thereby disrupting the network of interactions among water molecules, charged residues and divalent cation/s observed in different members of the superfamily of DHH phosphoesterases.33-35 (E) Proline 321 (corresponding to Pro369 in yeast) is a key part of the CDC45 interacting surface with Mcm2,26 given that in yeast it lies within 3.5Å of Ile289 of Mcm2 (corresponding to Ile211 in human MCM2). Additionally, this proline has a
key role in the N-capping of the alpha-helix localized between Leu370 and Gln374 in yeast Cdc45. Therefore, substitution of proline 321 to threonine is likely not only to have effects on CDC45-MCM2 interaction but also on CDC45 protein stability. The interacting pair Pro321 (in CDC45) and Ile211 (corresponding to Ile289 in Mcm2) are shown in sticks (green) inside their van der Waals surfaces.

**Figure 5.** Synonymous *CDC45* Variants Alter Levels of Alternative Splicing of Exon 4 in Lymphoblastoid Cell Lines

(A) The synonymous variant c.318C>T present in P1 increases the ratio of exon3/5 transcript compared to controls. (i) RT-PCR demonstrating an enrichment in the exon3/5 lower band. (ii) Results of qRT-PCR to assay the relative amounts of exon 4 in P1, P2 and four unaffected controls. Products were amplified with primers in exons 3 and 4, and compared with products generated from primers in exons 1 and 3. cDNA from P1 showed a 0.43-fold reduction in exons 3-4 relative to exons 1-3. Levels of exons 5-6 compared with exons 1-3 are also shown, no differences were observed. Error bars, standard deviation. n=3 experimental replicates of qPCR. (B) The synonymous variant c.333C>T together with the *trans* c.203A>G, p.Glu68Arg splice site variant identified in P9-1 and P9-2, increases aberrant splicing across this region of the gene. (i) RT-PCR demonstrating an increase in exon3/5 transcript and the creation of a novel transcript where exon 3 has been skipped due to the c.203A>G mutation. (ii) Total RNA extracted from LCLs derived from P9-1 was analyzed by qRT-PCR. Full length only transcripts were amplified using a forward primer (F 2/3) spanning the exon 2-exon 3 boundary and a reverse primer (R 4/5) spanning the exon 4-exon 5 boundary. The transcript missing exon 4 was specifically amplified using the F 2/3 primer paired with a reverse primer (R 3/5) which spanned the exon 3-exon 5 boundary. Total amount of minus exon 4 (-Ex4) and full length (FL) transcript was normalized to *GAPDH* for P9-1 and control.
Error bars indicate standard deviation (n = 3 experiments). A two tailed, unpaired student’s t-test was performed and p-values are indicated.

Figure 6. CDC45 Protein Levels are Significantly Reduced in Lymphoblastoid Cell Lines and Primary Amniocytes

Cell lines from affected individuals (P1, P2, P9-1) and amniocytes derived from affected fetuses (P12-1 and P12-2) demonstrate a significant reduction in endogenous CDC45 levels compared to three independent controls (LCL samples - one way ANOVA comparing all LCL samples against C1, NS, p > 0.01, ****p < 0.0001, n = 5 biological replicates; amniocyte samples - one way ANOVA comparing all amniocyte samples against C4. ***p < 0.001, ****p < 0.0001, n = 3 biological replicates).
Table 1. Mutations Identified in *CDC45*.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Country of Origin</th>
<th>Allele 1</th>
<th>Allele 2</th>
<th>Segregation</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3</td>
<td>USA</td>
<td>c.653+5G&gt;A (SE)</td>
<td>c.1487C&gt;T, p.Pro496Leu</td>
<td>Het, M, P</td>
</tr>
<tr>
<td>P4</td>
<td>Bangladesh</td>
<td>c.1A&gt;C, p.Met1?</td>
<td>c.1388C&gt;T, p.Pro463Leu</td>
<td>nps</td>
</tr>
<tr>
<td>P10c</td>
<td>New Zealand</td>
<td>[464A&gt;G; 961C&gt;A], p.[Glu155Gly; Pro321Thr]</td>
<td>1440+14C&gt;T (SE)</td>
<td>Het, M, P</td>
</tr>
<tr>
<td>P12-1</td>
<td>Netherlands</td>
<td>(485+1_486-1)_(630+1_631-1)del, p.Ile115_Glu162del</td>
<td>893C&gt;T, p.Ala298Val</td>
<td>Het, M, P</td>
</tr>
</tbody>
</table>

Refseq Accession: NM_003504.4 SE: splicing effect. Het, compound heterozygous in affected individual, nps, no parental samples available, M, mutation identified in mother, P, mutation identified in father, Hom, homozygous in affected individual. *Mutation previously reported28 (note mutation numbering differs in previous publication due to different reference transcript). bNumbers in brackets indicate number of clinically unaffected siblings shown not to have inherited the compound heterozygous genotype. cSubject P10 segregates two rare missense variants on one allele, in combination with a splice region mutation on the second allele. Based on conservation of CDC45 residues across different species the p.Pro321Thr variant is more likely to be deleterious as this residue is conserved through to *S. cerevisiae* (Figure 3).
Table 2. Clinical Characteristics of Individuals with Mutations in *CDC45*.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Consan</th>
<th>Gender</th>
<th>Gest.</th>
<th>Birth, SD</th>
<th>Current Exam, SD</th>
<th>MGS Features</th>
<th>Thin Eyebrows</th>
<th>Developmental Delay</th>
<th>Craniosynostosis</th>
<th>Other Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lgt (cm)</td>
<td>OFC (cm)</td>
<td>Hgt (cm)</td>
<td>OFC (cm)</td>
<td>Wgt (kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFC (cm)</td>
<td>Wgt (kg)</td>
<td>Wgt (kg)</td>
<td>Wgt (kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>N</td>
<td>M</td>
<td>40</td>
<td>NA</td>
<td>NA</td>
<td>-0.7 (3.2)</td>
<td>-0.4 (55.5)</td>
<td>+1.3 (85.7)</td>
<td>-</td>
<td>right unicoronal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>urethral stricture, mild 2/3/4 synactyly of hands</td>
</tr>
<tr>
<td>P2</td>
<td>N</td>
<td>F</td>
<td>38</td>
<td>NA</td>
<td>NA</td>
<td>-1.2 (2.5)</td>
<td>-0.9 (47.6)</td>
<td>-0.8 (15.3)</td>
<td>-</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bicoronal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>anterior anus, bilateral strabismus</td>
</tr>
<tr>
<td>P3</td>
<td>N</td>
<td>M</td>
<td>38</td>
<td>NA</td>
<td>NA</td>
<td>-1.7 (2.4)</td>
<td>-3.6 (50.5)</td>
<td>-3.9 (35.3)</td>
<td>+</td>
<td>mild</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bicoronal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R choanal atresia, high palate, imperforate anus, vesicoureteral reflux, hypospadias, 2-3 syndacalty of toes, scoliosis, C1-C3 and C4-C7 fusion, bilateral radial head dislocation</td>
</tr>
<tr>
<td>P4</td>
<td>N</td>
<td>F</td>
<td>36</td>
<td>NA</td>
<td>-2.9 (28.5)</td>
<td>-3.2 (1.45)</td>
<td>-7.7 (48)</td>
<td>-6.1 (9.9)</td>
<td>+</td>
<td>severe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>large anterior fontanelle (x-ray)</td>
</tr>
<tr>
<td>P5</td>
<td>3rd</td>
<td>F</td>
<td>40</td>
<td>NA</td>
<td>NA</td>
<td>-4.7 (1.5)</td>
<td>-4.6 (93)</td>
<td>-7.5 (9.2)</td>
<td>+</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>copper-beating on skull radiograph</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cleft palate, bowed legs, anorectal malformation</td>
</tr>
<tr>
<td>P6</td>
<td>N</td>
<td>M</td>
<td>34</td>
<td>0.3 (46.5)</td>
<td>-1.1 (30)</td>
<td>-1.2 (1.88)</td>
<td>-4.8 (145)</td>
<td>-8.4 (32.5)</td>
<td>+</td>
<td>severe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bicoronal and bilamboild</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AV block grade II, SN hearing loss, joint laxity, chiari I malformation, myopia</td>
</tr>
<tr>
<td>P7-1</td>
<td>1st</td>
<td>M</td>
<td>term</td>
<td>-4 (43)</td>
<td>-4 (30)</td>
<td>-2.5 (2.4)</td>
<td>-4.1 (83)</td>
<td>-6 (8.5)</td>
<td>+</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>coronal, sagittal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AV block grade II, SN hearing loss, joint laxity, chiari I malformation, myopia</td>
</tr>
<tr>
<td>P7-2</td>
<td>1st</td>
<td>F</td>
<td>term</td>
<td>-4.9 (41)</td>
<td>-2.9 (31)</td>
<td>-2.2 (2.45)</td>
<td>-3.5 (94)</td>
<td>-4 (11.5)</td>
<td>+</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>coronal, sagittal</td>
</tr>
<tr>
<td>P8</td>
<td>N</td>
<td>F</td>
<td>37</td>
<td>-0.4 (47)</td>
<td>-4.6 (27)</td>
<td>-1.7 (2.14)</td>
<td>-4.9 (82)</td>
<td>-7.6 (7.5)</td>
<td>+ lowset</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bicoronal and bilamboild, broad patent sagittal with bifid metopic suture</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>vestibular, anterior anus, hearing mild conduction delay, propstosis, VSD, duodenal stenosis</td>
</tr>
<tr>
<td>P9-1</td>
<td>N</td>
<td>M</td>
<td>42</td>
<td>-1.4 (50)</td>
<td>-1.5 (3.2)</td>
<td>7y</td>
<td>-1.3 (115)</td>
<td>-0.4 (22)</td>
<td>+</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>high arched palate, micropenis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>P9-2</td>
<td>N</td>
<td>M</td>
<td>term</td>
<td>0.5</td>
<td>-1.7</td>
<td>-1.2</td>
<td>16m</td>
<td>-2.5</td>
<td>-4.7</td>
<td>-3.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(52)</td>
<td>(33)</td>
<td>(3.0)</td>
<td>(73)</td>
<td>(43)</td>
<td>(7.5)</td>
<td>(2.5)</td>
<td>(49)</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>N/A</td>
<td>+</td>
<td>none</td>
<td>bicoronal with widely patent metopic and sagittal sutures</td>
<td>none</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P10</td>
<td>N</td>
<td>F</td>
<td>36</td>
<td>NA</td>
<td>-1.8</td>
<td>-1.5</td>
<td>25y</td>
<td>-2.5</td>
<td>-4.7</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(30)</td>
<td>(2.04)</td>
<td>(149)</td>
<td>(49)</td>
<td></td>
<td>(2.5)</td>
<td>(49)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>none</td>
<td>bicoronal</td>
<td>high palate, hearing loss, breast agenesis, heart block</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P11</td>
<td>1st</td>
<td>F</td>
<td>40</td>
<td>NA</td>
<td>-4.0</td>
<td>4y 7m</td>
<td>-2.5</td>
<td>-4.6</td>
<td>-3.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1.75)</td>
<td>(95)</td>
<td>(4.6)</td>
<td>(12)</td>
<td></td>
<td>(2.5)</td>
<td>(49)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>none</td>
<td>coronal and lambdoid</td>
<td>small ASD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P12-1</td>
<td>N</td>
<td>F</td>
<td>22+3a</td>
<td>-1.9</td>
<td>-3.0</td>
<td>TOP</td>
<td>+</td>
<td>Not reported</td>
<td>+</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(25)</td>
<td>(15.5)</td>
<td>(0.33)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P12-2</td>
<td>N</td>
<td>M</td>
<td>30+5a</td>
<td>-0.4</td>
<td>-1.1</td>
<td>TOP</td>
<td>lowset</td>
<td>Not reported</td>
<td>+</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(39.1)</td>
<td>(24)</td>
<td>(1.15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SD, standard deviation. Calculated using LMSgrowth and adjusted for sex and gestation, with the exception of a, where Z-scores were calculated using the Fenton 2013 Growth Calculator. bmeasurement at 15 years of age, after surgery. cmeasurement at 5 months of age. NA, not available; TOP, termination of pregnancy.